Would you consider adding midostaurin to azacitadine in elderly patients with newly diagnosed AML with FLT3-ITD mutations in the frontline setting?

Yes, would consider adding midostaurin to azacitidine in an elderly patient with newly diagnosed AML with FLT3 as long as if ITD allelic ratio is high where benefit outweighs risks of cytopenias and infections. Dose reductions can be considered based on tolerance. I would use the same regimen as stu...